Skip to content
Markets
SPY700.42▼ -2.16%QQQ620.16▼ -3.86%DIA487.10▼ -0.75%GLD323.35▼ -3.53%TLT81.31▲ +1.20%BABA82.90▼ -0.49%NIO2.48▼ -6.58%PDD85.08▼ -1.08%Realtime derived data
Octans ResearchOCTANS RESEARCHWaitlist
A Wall Street street sign in front of the flag-hung facade of the New York Stock Exchange.
Source: Billie Grace Ward, CC0, via Wikimedia Commons

CG Oncology CEO Arthur Kuan buys $2.4 million of shares

Open market purchase reported on Form 4, filed Nov 18, 2026.

Octans ResearchPublished

Snapshot

Arthur Kuan, Chief Executive Officer of CG Oncology (CGON), bought 30,000.32 shares in open market purchases on Nov 18, 2026, about $2.4 million at an average price of $78.88 a share, according to a Form 4 filed with the SEC on Nov 18, 2026.

Coverage
Independent Research
Prepared by
Octans Research
Tickers
CGON
As of

Market Data

Latest prices for the companies covered in this article
Company1D %Price
($CGON)▼ −1.26%80.87

as of 12:33 ET · Realtime derived data

What We Know

The filing lists 1 open market purchase line: • Nov 18, 2026: 30,000.32 shares at $78.88.

After the last purchase, the filing reports 228,916.32 shares held directly in that account.

Octans View

The purchases raised the holding reported in that account by about 15%, computed from the filed share counts. An open market purchase is made with the insider's own money at the market price, unlike option exercises or stock awards, which this brief excludes. The filing does not say why the insider bought.

Bear Case · Room for Disagreement

Limits. Insiders must report trades within two business days; this brief covers one filing and does not net it against sales by the same person or other insiders. Prices are as filed; where a line shows a weighted average, the filing's footnotes give the range.

Method and source. Octans Research reads the structured Form 4 filed with the SEC, keeps open market purchases (code P) only, and computes the total value and the average price from the filed share counts and prices. The filed price must sit within 25% of the closing price on the trade date. The text is generated by a fixed template; no model wrote it.

Chart

$CGON adjusted close, last 6 months $CGON adjusted close, last 6 months: series rising from 61.9 to 81.9 (+32.3%) from 2026-05-26 to 2026-11-19. Scale 50 to 90. 5060708090 2026-05-262026-11-19 $CGON ADJUSTED CLOSE, LAST 6 MONTHS +32.3% 81.9
Source: Tiingo · As of 2026-11-19Indicative, not investment advice.

Sources

  1. [1]SEC EDGAR — Form 4 filed by Arthur Kuan for CG Oncology, Nov 18, 2026

These are the sources this piece was drafted from. How we verify. Found an error? Tell us and we correct it in public.

$2.4M

Arthur Kuan, Chief Executive Officer of CG Oncology (CGON), bought 30,000.32 shares in open mar… · Snapshot

Related coverage

More on $CGON

4 reports